 4D pharma PLC LON:DDD, NASDAQ:LBPS hailed 2020 as a transformational year for the company. In its full-year results statement, the company listed the publication of the first proof-of-concept data for MRx0518 in last-line cancers and the journey towards a listing on NASDAQ as highlights of the year. 